Selecky Christobel 4

What Happened Christobel Selecky, a director of ImmunityBio (IBRX), exercised options and sold the resulting shares in two tranches. On 2026-01-16 she exercised 50,000 shares at $2.98 ($149,000) and sold 50,000 shares at $5.00 ($250,000). On 2026-01-20 she exercised 25,000 shares at $2.98 ($74,500) and sold 25,000 shares at $7.51 ($187,650). Aggregate: 75,000 shares exercised for $223,500 and 75,000 shares sold for $437,650. The filing also reports related derivative dispositions at $0 (see Key Details).

Key Details

• Transaction dates and prices:
  • 2026-01-16: Exercised 50,000 @ $2.98 (acquired, $149,000); sold 50,000 @ $5.00 (disposed, $250,000); derivative disposal reported @ $0 for 50,000.
  • 2026-01-20: Exercised 25,000 @ $2.98 (acquired, $74,500); sold 25,000 @ $7.51 (disposed, $187,650); derivative disposal reported @ $0 for 25,000.
• Total exercised: 75,000 shares for $223,500. Total sold: 75,000 shares for $437,650.
• Shares owned after transaction: Not specified in the provided filing.
• Notable footnotes:
  • F1: The sales were effected under a Rule 10b5-1 trading plan adopted June 12, 2025.
  • F2: The $7.51 sale price for 25,000 shares is a weighted average of sales in the $7.50–$7.52 range; seller will provide breakdown on request.
  • F3: An award referenced in the filing vested 100% on June 12, 2023.
• Exhibit: Exhibit 24 (Power of Attorney) is attached to the filing.
• Filing date: Form 4 filed 2026-01-21 covering trades on 2026-01-16 and 2026-01-20. (No explicit late-filing statement in the provided data.)

Context

• These entries are option exercises (transaction code M) followed by open-market sales (S). When exercise and sale occur close together, it functions like a cashless exercise—the insider realizes the spread between strike and sale price but does not necessarily indicate a change in view on the company.
• Sales were executed under a pre-established 10b5-1 plan, which is commonly used to automate insider sales and reduce concerns about opportunistic timing.
• The $0 disposals reported for derivatives generally reflect conversion/settlement of derivative instruments and are distinct from the open-market sales that generated cash.